Business Context and Reporting Period
Spruce Biosciences, Inc. (SPRB) is a late-stage biopharmaceutical company developing tildacerfont, a CRF1 receptor antagonist, for the treatment of classic congenital adrenal hyperplasia (CAH), polycystic ovary syndrome (PCOS), and major depressive disorder (MDD). This summary covers the unaudited quarterly period ended June 30, 2024.
Key Financial Metrics
| Metric | Q2 2024 (3 Months) | Q2 2023 (3 Months) | YTD 2024 (6 Months) | YTD 2023 (6 Months) |
|---|---|---|---|---|
| Collaboration Revenue | $1.6 million | $2.2 million | $3.6 million | $4.1 million |
| Net Loss | $(9.2) million | $(12.8) million | $(20.8) million | $(25.6) million |
| Net Loss Per Share | $(0.22) | $(0.32) | $(0.51) | $(0.71) |
| Cash and Cash Equivalents | $69.7 million (as of June 30, 2024) | |||
| Accumulated Deficit | $218.0 million (as of June 30, 2024) | |||
| Term Loan Outstanding | $2.6 million principal (Carrying value $2.5 million) | |||
| Operating Cash Flow (YTD) | $(26.1) million used |
Material Changes vs. Prior Period
- Revenue Decline: Collaboration revenue decreased by approximately 26% year-over-year for the quarter and 12% year-over-year for the six-month period. This is primarily due to the recognition schedule of the upfront payment from the Kaken Pharmaceutical license agreement.
- Expense Reduction: Research and development (R&D) expenses decreased significantly by $5.0 million for the quarter and $6.4 million for the six-month period compared to the prior year. This reduction was driven by the termination of the CAHmelia-203 clinical trial, completion of the POWER study, and a reduction in headcount (approximately 21% in March 2024).
- Improved Loss Profile: The net loss narrowed by $3.6 million for the quarter and $4.8 million for the six-month period, largely attributable to the decrease in R&D spending.
- Cash Position: Cash and cash equivalents decreased from $96.3 million at year-end 2023 to $69.7 million at June 30, 2024, reflecting operating cash burn.
Outlook, Risks, and Unusual Items
Clinical Developments
- CAHmelia-203 (Adult CAH): The Phase 2b trial failed to meet its primary efficacy endpoint and was terminated in March 2024. Low patient compliance contributed to lower-than-expected drug exposure.
- CAHmelia-204 (Adult CAH): A second Phase 2b trial is ongoing with a differentiated patient population. Topline results are expected in Q4 2024.
- CAHptain-205 (Pediatric CAH): Met efficacy endpoints in initial cohorts, though activity was less consistent than anticipated. The trial has been amended to include additional dose-ranging cohorts. Results expected in Q4 2024.
- PCOS (POWER Study): Phase 2 results showed significant reduction in adrenal androgens (DHEAS) and increase in SHBG versus placebo. The company is evaluating strategic collaboration opportunities for this indication.
- MDD: Entered an agreement with HMNC Holding GmbH in May 2024 to fund a Phase 2 proof-of-concept study using a genetic selection tool.
Liquidity and Capital Resources
Management believes current cash resources ($69.7 million) are sufficient to fund operations and debt obligations for at least 12 months following the filing date. The company expects to continue incurring significant losses and will require substantial additional financing to advance clinical programs and commercialize tildacerfont.
Material Risks
- Nasdaq Delisting Risk: On April 26, 2024, the company received notice from Nasdaq that its stock closing bid price had been below $1.00 for 30 consecutive days. It has until October 23, 2024, to regain compliance.
- Single Product Dependence: The company's success depends entirely on tildacerfont. Failure of ongoing trials (CAHmelia-204, CAHptain-205) would materially harm the business.
- Financing Needs: Failure to raise additional capital could force the company to delay, reduce, or eliminate product development programs.
- Asset Acquisition: In June 2024, the company entered a "stalking horse" agreement to acquire assets from Eiger BioPharmaceuticals (Avexitide) for $10.0 million, subject to bankruptcy court approval and auction. The company was designated the back-up bidder with a net purchase price of $34.7 million.
Investor Verification Checklist
- Verify the timeline and criteria for regaining Nasdaq compliance (closing bid price of $1.00 for 10 consecutive days) before the October 23, 2024 deadline.
- Monitor the Q4 2024 topline data readouts for the CAHmelia-204 and CAHptain-205 trials, which are critical for the registrational pathway.
- Assess the status of the Eiger BioPharmaceuticals asset acquisition and the likelihood of the auction resulting in a higher bid.
- Review the company's cash burn rate and potential dilution from future equity or debt financing required to extend the runway beyond 2025.
- Confirm the terms and progress of the HMNC collaboration for the MDD indication and any potential partnerships for PCOS.